Multiple Sclerosis Clinical Trial
Official title:
Gait Rehabilitation for Multiple Sclerosis Using Robot-assisted Body-weight-supported Treadmill Training (Lokomat)
Multiple sclerosis is a degenerative disease that affects more than 400,000 people in the US
alone. MS is in fact the most common disabling neurological disorder in young adults.
Symptoms of the disease can include problems with balance, walking, fatigue, weakness and
vision. Over 85% of people with Multiple Sclerosis have problems walking. This can cause
them to fall or have a constant fear of falling. To prevent falling, MS patients rely on
equipment, such as walkers and canes. These costs can cause financial difficulties for MS
patients and families.
A significant problem that is only recently being studied is the relationship between
falling and MS. Recent studies have shown that MS patients fall more often than those
without MS, and also fall more than the elderly population. The consequent fear of falling
is also an important problem, as those worried about falling will probably change their
daily habits to lower their risk. This can mean keeping from certain physical and social
activities or even staying indoors. Thus, falls and fear of falling can have negative
medical, physical, psychological, and social consequences for the patient.
Improving patients' walking may help reduce falls and the fear of falling. Treadmill
training has been shown to improve walking in patients with MS and to lower their risk of
falling. One way to train patients on a treadmill is with the use of robots that can help
move their limbs in a more normal way. This kind of robot-assisted treadmill training may
provide even greater benefits than treadmill training alone.
The study is expected to last 6-7.5 months. One group of participants will receive weekly
telephone calls and will be asked questions on other physical activities, falls, and
activity limitations the patient had during the week. Participants assigned to
robot-assisted treadmill training will receive twice weekly training session for 8 weeks,
for a total of 16 sessions. Each session will last about 65 to 90 minutes.
The goal of this study is to see if robot-assisted treadmill training will reduce falls and
fear of falling in patients with MS. Robot-assisted treadmill training has been shown to be
effective in reducing falls and fear of falling in Parkinson's disease patients. This type
of training has not been tested in patients with Multiple Sclerosis. The proposed study will
help to address this gap and also provide additional data on other possible improvements due
to robot-assisted treadmill training including ambulation, social participation, fatigue,
and balance.
Status | Terminated |
Enrollment | 20 |
Est. completion date | June 2008 |
Est. primary completion date | June 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: 1. Diagnosis of MS by McDonald criteria 2. Ability to clearly understand written and oral direction in English 3. Self-reported gait problem 4. One or more falls in the past 6 months 5. The ability to walk 25 feet with no more than a cane for assistance (The subject must be comfortable using a cane) 6. Age 18-70 7. Written informed consent to participate in the study 8. Approval from subject's primary care physician for physical activity Exclusion Criteria: 1. No relapse within the last 3 months 2. No more than two relapses within the past 12 months 3. Recent myocardial infarction 4. Uncontrolled hypertension or diabetes 5. Symptomatic fall in blood pressure when standing 6. Vascular claudication or pitting edema 7. Cognitive impairments that limit comprehension of protocol instructions (assessed by Comprehension Test of Consent Form) 8. Body weight over 150 kg 9. FES-I < 25 10. Lower extremity injuries that limit range of motion or function 11. Joint problems (hip or leg) that limit range of motion or cause pain with movement 12. Unstable fractures 13. Pressure sores with any skin breakdown in areas in contact with the body harness or the robot-driven gait orthotic apparatus 14. Currently enrolled in an alcohol or drug treatment program 15. A complicating medical condition that would prevent completion of the trial 16. Enrolled in or planning to enroll in another interventional research trial using procedures proposed to enhance or limit the function of the upper or lower extremities (such as adjuvant rehabilitation or Botox injections) during the 24 weeks of participation 17. A difference of more than 2cm between subjects' right and left leg lengths 18. Unable to be properly fit into the harness or Lokomat device 19. Hypertonicity or spasticity that it interferes with a proper fit into the Lokomat 20. Pregnancy at enrollment, as determined by a home pregnancy test kit at screening visit |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Providence VA Medical Center | Providence | Rhode Island |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Frequency of Falls | 6-7.5 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05528666 -
Risk Perception in Multiple Sclerosis
|
||
Completed |
NCT03608527 -
Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05532943 -
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|
Phase 1/Phase 2 | |
Completed |
NCT02486640 -
Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
|
||
Completed |
NCT01324232 -
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Active, not recruiting |
NCT04380220 -
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
|
||
Completed |
NCT02835677 -
Integrating Caregiver Support Into MS Care
|
N/A | |
Completed |
NCT03686826 -
Feasibility and Reliability of Multimodal Evoked Potentials
|
||
Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
Withdrawn |
NCT06021561 -
Orofacial Pain in Multiple Sclerosis
|
||
Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
Recruiting |
NCT04798651 -
Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
|
N/A | |
Active, not recruiting |
NCT05054140 -
Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
Completed |
NCT05447143 -
Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis
|
N/A | |
Recruiting |
NCT06195644 -
Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients
|
Phase 1 | |
Completed |
NCT04147052 -
iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis
|
N/A | |
Completed |
NCT03591809 -
Combined Exercise Training in Patients With Multiple Sclerosis
|
N/A | |
Completed |
NCT03594357 -
Cognitive Functions in Patients With Multiple Sclerosis
|
||
Completed |
NCT03269175 -
BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies
|
Phase 4 |